MEDLINE/PubMed Journal Browser Search

Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

Title: In vitro chemosensitivity of leukemic progenitor cells (AML-CFU) to a combination of mafosfamide lysine (ASTA-Z 7654) and etoposide (VP16-213).
Author: Deconinck E, Tamayo E, Hervé P.
Journal: Bone Marrow Transplant; 1990 Jan; 5(1):13-8. PubMed ID: 2297586.
Abstract:
The inhibitory effects of mafosfamide lysine, ASTA-Z 7654 (ASTA-Z) and etoposide, (VP16-213) on human leukemic progenitor cells (AML-CFU) were studied using a clonogenic assay. AML-CFU were shown to be less sensitive than human promyelocytic leukemia cells (HL-60) to the toxic effects of these two drugs. The mean log kill obtained for the AML-CFU from 12 patients was only 0.95 and 0.93 for 50 micrograms/ml ASTA-Z and etoposide respectively. For normal progenitor cells (CFU-GM) the maximum log kill increased to 2 log at 50 micrograms/ml ASTA-Z or etoposide and for HL-60 cells more than 4 log kill values were obtained for the same drug concentrations. When the two drugs were used in combination the log kill value increased to 1.75 for AML-CFU. Furthermore, in addition to classic incubation parameters (temperature, cell concentration, red blood cell contamination and time) the treatment efficiency was influenced by the incubation sequence of the two drugs. When ASTA-Z and etoposide were incubated together (Z/VP) or etoposide prior to ASTA-Z (VP + Z) log kill values for drug concentrations of 20 and 50 micrograms/ml were 0.72 and 1.41 respectively. However, when cells were incubated with ASTA-Z prior to etoposide (Z + VP) values of 1.1 and 1.75 were obtained for drug concentrations of 20 and 50 micrograms/ml respectively (p less than or equal to 0.05 between Z + VP and the two other sequences).(ABSTRACT TRUNCATED AT 250 WORDS)

[Abstract] [Full Text] [Related] [New Search]